Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Fallopian Tube Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Ovarian Carcinoma
- Advanced Pancreatic Adenocarcinoma
- Advanced Primary Peritoneal Carcinoma
- Fallopian Tube High Grade Serous Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Unresectable Pancreatic Adenocarcinoma
Interventions
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Diagnostic Imaging Testing
- DRUG: Elimusertib
- DRUG: Gemcitabine
Sponsor
National Cancer Institute (NCI)